BeiGene to Present at the Cowen and Company's 40th Annual Health Care Conference

CAMBRIDGE, Mass. and BEIJING, China, Feb. 25, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. BGNE HKEX: 06160))), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Company will present at the Cowen and Company's 40^th Annual Health Care Conference in Boston, MA on Tuesday, March 3, 2020 at 11:20 a.m. ET.

A live webcast can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available following the event for 90 days.

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 3,400 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. In the United States, BeiGene markets BRUKINSA™ (zanubrutinib) and in China, the Company has received approval to market its anti-PD-1 antibody tislelizumab and markets ABRAXANE^® (nanoparticle albumin-bound paclitaxel), REVLIMID^® (lenalidomide), and VIDAZA^® (azacitidine) under a license from Celgene Logistics Sarl, a Bristol-Myers Squibb company, and plans to market XGEVA^® (denosumab) under a license from Amgen.^1,2 For more information, please visit www.beigene.com.

Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com 

Media Contact
Liza Heapes or Vivian Ni
+1 857-302-5663 or +1 857-302-7596
media@beigene.com 

¹ ABRAXANE^® is registered trademark of Abraxis Bioscience LLC, a Bristol-Myers Squibb company; REVLIMID^® and VIDAZA^® are registered trademarks of Celgene Corporation, a Bristol-Myers Squibb company. 

² XGEVA^® is a registered trademark of Amgen.